Neumora Therapeutics, Inc. (NMRA)

In our clinical protocols, the termination of navacaprant after missing primary endpoints in KOASTAL-2 and -3 dealt a heavy blow to our confidence in their core depression asset. However, attention has rapidly pivoted to the V1a receptor antagonist NMRA-511 for Alzheimer's disease agitation and the M4 positive allosteric modulator NMRA-898 in schizophrenia. We are closely watching the MAD cohort results slated for late 2026 to see if dose selection for a Phase 2b study can redeem their CNS platform.

On our macro desk, NMRA is viewed as a high-risk micro-cap trading around $1.35 to $1.39, deeply discounted from prior highs. Even with prominent institutional holders like Amgen (18.82%) and Arch Venture Partners (14.80%) anchoring the cap table, retail sentiment is tainted by active securities fraud investigations initiated by firms like Levi and Korsinsky following the navacaprant collapse.

Risk management perspective: The company executed a 35% workforce reduction to curb burn, trimming RandD expenses down to $29.3M and general/administrative expenses to $12.9M in Q2 2026. With $116.8M in cash at the end of June 2026, management has successfully stretched the operational runway into the third quarter of 2027, mitigating immediate near-term dilution risks despite a net loss of $43.1M for the quarter.

From a bio-analytical point of view, the preclinical profile of NMRA-215 (an NLRP3 inhibitor for obesity) initially raised yellow flags due to unexpected toxicological findings. Fortunately, subsequent 13-week rat toxicology updates in mid-2026 provided favorable resolutions, clearing the path for planned clinical study initiations by the end of 2026.

Looking at sell-side positioning, analysts remain surprisingly bullish despite the pipeline pivot, with 78% maintaining a Buy rating and consensus price targets clustering significantly higher than the current penny stock valuation. Firms like Guggenheim, H.C. Wainwright, and Needham continue to support the long-term thesis, though execution on NMRA-511 and NMRA-898 milestones will dictate whether these targets are achievable.